Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL study

Bitget2026/10/02 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Johnson & Johnson disclosed new two-year Phase 3 ICONIC-TOTAL results for ICOTYDE (icotrokinra) in high-impact plaque psoriasis.
Results were already presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress 2026.
Data showed durable skin clearance in difficult-to-treat areas, supporting ICOTYDE’s positioning as a first-line systemic therapy.
Safety remained consistent with prior findings, with no new issues flagged over the two-year follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610020600PR_NEWS_USPR_____NY62204) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL study

You may also like

Crypto prices